MSD
Welcome,         Profile    Billing    Logout  
 4 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ljung, Tryggve
KEYNOTE-051, NCT02332668 / 2014-002950-38: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/)

Checkmark Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Dec 2019 - Dec 2019: Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Recruiting
1/2
370
Europe, US, RoW
Pembrolizumab, MK-3475
Merck Sharp & Dohme LLC
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
10/27
10/27
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27

Download Options